Order results by:
| Issue | Title | |
| Vol 14, No 3 (2018) | APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova | ||
| "... of efficacy and safety of apixaban in patients with AF, depending on the presence of CHD, PAD, concomitant use ..." | ||
| Vol 16, No 5 (2020) | Pharmacokinetics and Pharmacogenetics of Apixaban | Abstract similar documents |
| A. V. Savinova, M. M. Petrova, N. A. Shnayder, E. N. Bochanova, R. F. Nasyrova | ||
| "... Apixaban is oral anticoagulant, it is widely used in prevention of stroke in non-valvular atrial ..." | ||
| Vol 12, No 3 (2016) | THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE | Abstract PDF (Eng) similar documents |
| A. V. Kryukov, D. A. Sychev, D. A. Andreev, A. V. Ryabova, N. P. Denisenko, M. A. Loskutnikov, O. I. Vinogradov, M. A. Domashenko | ||
| "... Aim. To study pharmacokinetics of apixaban in patients with atrial fibrillation and cardioembolic ..." | ||
| Vol 11, No 5 (2015) | Practical aspects of apixaban use in clinical practice: continuing the theme | Abstract similar documents |
| S. N. Bel'diev | ||
| "... Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova | ||
| Vol 10, No 3 (2014) | EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION | Abstract similar documents |
| "... European Medicines Agency approved apixaban use in cardioversion. ..." | ||
| Vol 11, No 2 (2015) | PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST | Abstract similar documents |
| D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii | ||
| "... Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base ..." | ||
| Vol 11, No 6 (2015) | Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events | Abstract similar documents |
| O. V. Shatalova | ||
| "... Aim. Pharmacoeconomic analysis of apixaban use compared to conventional therapy in patients ..." | ||
| Vol 18, No 5 (2022) | Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova | ||
| "... thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According ..." | ||
| Vol 13, No 1 (2017) | CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova | ||
| "... and apixaban in patients with non-valvular atrial fibrillation (AF) and to assess the impact of the both ..." | ||
| Vol 13, No 5 (2017) | DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov | ||
| Vol 16, No 2 (2020) | The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| Vol 14, No 2 (2018) | NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING | Abstract similar documents |
| Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov | ||
| "... . In comparison of different DOACs against each other apixaban demonstrated lower bleeding risk while patients ..." | ||
| Vol 13, No 5 (2017) | Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells | Abstract similar documents |
| Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov | ||
| Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... (warfarin), antiplatelet therapy (acetylsalicylic acid) and novel oral anticoagulants such as apixaban ..." | ||
| Vol 18, No 3 (2022) | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art | Abstract similar documents |
| S. R. Gilyarevsky | ||
| "... interactions of apixaban, rivaroxaban and dabigatran with the drugs most frequently used in patients ..." | ||
| Vol 18, No 6 (2022) | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis | Abstract similar documents |
| L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev | ||
| "... Aim. To investigate the effect of ABCB1 gene carriage and interdrug interactions on apixaban ..." | ||
| Vol 12, No 4 (2016) | Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true | Abstract similar documents |
| Yu. A. Bunin, S. V. Miklishanskaya | ||
| Vol 13, No 1 (2017) | DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT | Abstract similar documents |
| D. А. Napalkov, A. A. Sokolova, V. V. Fomin | ||
| "... anticoagulants, apixaban is associated with the best adherence to treatment and lowest bleeding incidence ..." | ||
| Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
| A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
| "... 1045642 polymorphisms. ABCB1 gene rs4148738 polymorphism was associated with higher apixaban peak ..." | ||
| Vol 7, No 5 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES | Abstract similar documents |
| Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy | ||
| Vol 9, No 3 (2013) | ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT | Abstract similar documents |
| E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts | ||
| Vol 11, No 3 (2015) | ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran ..." | ||
| Vol 9, No 4 (2013) | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS | Abstract similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova | ||
| "... Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban ..." | ||
| Vol 10, No 4 (2014) | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..." | ||
| Vol 16, No 1 (2020) | Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice | Abstract similar documents |
| A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko | ||
| Vol 17, No 1 (2021) | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction | Abstract similar documents |
| Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya | ||
| Vol 17, No 2 (2021) | Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions | Abstract similar documents |
| V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto | ||
| "... : rivaroxaban - 180/384 (46,9%) patients, dabigatran etexilate - 110/384 (28,6%) patients, apixaban - 94/384 (24 ..." | ||
| Vol 15, No 5 (2019) | Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| Vol 10, No 3 (2014) | COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. V. Rudakova, V. A. Parfenov | ||
| "... anticoagulants such as apixaban, rivaroxaban and dabigatran. Administration of vitamin K antagonists (VKA ..." | ||
| Vol 12, No 2 (2016) | ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, A. V. Rodionov | ||
| "... and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic ..." | ||
| Vol 13, No 6 (2017) | PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS | Abstract similar documents |
| A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin | ||
| "... – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate ..." | ||
| Vol 15, No 6 (2019) | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation | Abstract similar documents |
| M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..." | ||
| Vol 16, No 1 (2020) | The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation | Abstract similar documents |
| A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva | ||
| "... , rivaroxaban – in 41.3% (n=178), apixaban – in 20.2% (n=87) of patients. Results. The incidence of new cases ..." | ||
| Vol 16, No 2 (2020) | Off-Label Medicines Use: Complex Problem of Modern Clinical Practice | Abstract similar documents |
| S. R. Gilyarevskiy | ||
| Vol 14, No 3 (2018) | THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE | Abstract similar documents |
| I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... long-term anticoagulant therapy with apixaban in a full dose (5 mg b.i.d.), and the patient ..." | ||
| Vol 14, No 4 (2018) | Hepatotoxicity of New Oral Anticoagulants | Abstract similar documents |
| A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin | ||
| Vol 16, No 6 (2020) | An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? | Abstract similar documents |
| T. V. Pavlova | ||
| Vol 15, No 4 (2019) | Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen | Abstract similar documents |
| A. I. Kochetkov, O. D. Ostroumova | ||
| "... profile and multimorbidity. In these terms, apixaban stands high among the DOAC class, and its high ..." | ||
| Vol 19, No 3 (2023) | Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants | Abstract similar documents |
| S. R. Gilyarevsky, N. K. Vereina, M. V. Golshmid | ||
| Vol 20, No 1 (2024) | Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis | Abstract similar documents |
| l. V. Fedina, i. N. Sychev, K. V. Mirzaev, A. V. Vardanyan, S. V. Glagolev, A. A. Kachanova, P. O. Bochkov, R. V. Shevchenko, S. N. Tuchkova, I. V. Sychev, S. P. Abdullaev, D A. Sychev | ||
| "... ) and rs4148738 (c.2692-2236C>T) genes on the plasma concentration of apixaban, on changes in prothrombin ..." | ||
| Vol 20, No 4 (2024) | Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients? | Abstract similar documents |
| N. M. Vorobyeva, I. P. Malaya, V. D. Zakiev, O. N. Tkacheva | ||
| Vol 12, No 5 (2016) | Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| I. S. Daabul, A. A. Sokolova, D. A. Napalkov | ||
| Vol 16, No 3 (2020) | Clinical and Pathophysiological Aspects of the Effect of Anticoagulants on Bone Tissue | Abstract similar documents |
| O. D. Ostroumova, I. V. Goloborodova | ||
| Vol 18, No 6 (2022) | Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants | Abstract similar documents |
| A. D. Aga, A. A. Sokolova, D. A. Napalkov | ||
| Vol 15, No 4 (2019) | According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention | Abstract similar documents |
| Company Pfizer | ||
| Vol 17, No 6 (2021) | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 | Abstract similar documents |
| I. S. Yavelov | ||
| Vol 14, No 2 (2018) | New Possibilities of Antithrombotic Therapy of Patients with Peripheral and Widespread Atherosclerotic Lesion | Abstract similar documents |
| A. L. Komarov, Е. S. Novikova, E. V. Guskova, Е. B. Yarovaya, A. N. Samko, E. Р. Panchenko | ||
| "... Atherosclerotic peripheral artery disease (PAD) is well-known thrombotic risk factor in different ..." | ||
| Vol 20, No 2 (2024) | Characteristics of the Russian population of patients with coronary artery disease or peripheral artery disease in the XATOA registry | Abstract similar documents |
| V. S. Arakelyan, A. D. Erlikh, N. Sh. Amirov, E. Dubar, K. Vogtlaender, S. Debus | ||
| "... disease (CAD) or peripheral artery disease (PAD) included in the XATOA study from Russian centers ..." | ||
| Vol 11, No 5 (2015) | Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism | Abstract similar documents |
| A. V. Rudakova | ||
| "... Aim. To assess the cost-effectiveness of apixaban in the treatment and secondary prevention ..." | ||
| Vol 9, No 2 (2013) | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES | Abstract similar documents |
| Z. M. Safiullina, S. V. Shalaev | ||
| "... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..." | ||
| Vol 16, No 6 (2020) | The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New? | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... , rivaroxaban, apixaban, and edoxaban) over the vitamin K antagonist warfarin in elderly patients with geriatric ..." | ||
| Vol 11, No 3 (2015) | PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT | Abstract similar documents |
| A. V. Rudakova | ||
| "... average prices of public bidding for the purchase of drugs (enoxaparin, dabigatran and apixaban) during ..." | ||
| Vol 16, No 2 (2020) | The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment | Abstract similar documents |
| К. V. Lobastov, I. V. Schastlivtsev | ||
| "... patients have been published: SELECT-D (rivaroxaban), HOKUSAI-VTE Cancer (edoxaban), ADAM VTE (apixaban ..." | ||
| Vol 16, No 4 (2020) | The Controversy Continues Again: which Direct Anticoagulant is More Effective and Safe when Administered to Patients with Atrial Fibrillation? | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... is inferior to apixaban in its ability to prevent ischemic stroke and systemic embolism and is more likely ..." | ||
| Vol 12, No 2 (2016) | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE | Abstract similar documents |
| S. V. Moiseev | ||
| "... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..." | ||
| Vol 17, No 5 (2021) | Gastrointestinal Bleeding: a Cardiologist's Point of View | Abstract similar documents |
| O. V. Averkov, L. N. Mishchenko | ||
| "... antagonists (warfarin) as well as direct oral anticoagulants (DOAC): dabigatran, rivaroxaban, apixaban ..." | ||
| Vol 21, No 2 (2025) | Anticoagulant therapy in patients with cardioembolic subtype of ischemic stroke and atrial fibrillation | Abstract similar documents |
| E. A. Naryshkina, M. I. Chashkina, E. S. Zadykyan, N. K. Kurbanalieva, E. M. Zakaryan, M. V. Serova, D. A. Andreev, A. G. Komarova, K. E. Eroshkin, A. A. Kulesh, D. A. Sychev | ||
| "... on outpatient ACT were included; rivaroxaban (n=56), apixaban (n=30), dabigatran etexilate (n=11), and warfarin ..." | ||
| Vol 18, No 1 (2022) | Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev, K. G. Pereverzeva, A. Yu. Timakova, A. S. Galus, S. S. Yakushin | ||
| "... among anticoagulants (36.7%). About a third of respondents were prescribed apixaban by a doctor (30 ..." | ||
| Vol 15, No 5 (2019) | Findings Released from NAXOS Analysis. Pfizer Company Press Release | Abstract similar documents |
| article Editorial | ||
| "... Компания Pfizer представила результаты когортного исследования NAXOS (EvaluatioN of ApiXaban in ..." | ||
| Vol 12, No 5 (2016) | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation | Abstract similar documents |
| N. A. Novikova, A. N. Volovchenko | ||
| "... showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... therapy turned out to be the most promising for clinical use, since studies with dabigatran and apixaban ..." | ||
| Vol 13, No 5 (2017) | WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT | Abstract similar documents |
| S. Yu. Martsevich, Y. V. Lukina | ||
| "... of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..." | ||
| Vol 17, No 5 (2021) | Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy | Abstract PDF (Eng) similar documents |
| E. S. Mazur, V. V. Mazur, N. D. Bazhenov, Yu. A. Orlov | ||
| "... .6%) started or continued taking rivaroxaban 20 mg 1 time/day and 3 (4.4%) started or continued taking apixaban ..." | ||
| Vol 14, No 5 (2018) | Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA | Abstract similar documents |
| Bayer Company Press Release | ||
| "... (ИБС) или симптоматическим заболеванием периферических артерий (ЗПА) с высоким риском ишемических ..." | ||
| Vol 15, No 6 (2019) | Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study) | Abstract similar documents |
| S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, S. N. Tolpygina, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, N. A. Komkova | ||
| "... recommended the use of rivaroxaban; 47 (23.4%) – the use of dabigatran and 43 (21.4%) – the use of apixaban ..." | ||
| Vol 15, No 6 (2019) | Markers of Endothelial Dysfunction: E-selectin, Endothelin-1 and von Willebrand Factor in Patients with Coronary Heart Disease, Including in Combination with Type 2 Diabetes Mellitus | Abstract similar documents |
| A. V. Zhito, A. O. Iusupova, E. V. Privalova, N. V. Khabarova, Yu. N. Belenkov | ||
| "... The prevalence of coronary heart disease (CHD) and type 2 diabetes mellitus (type 2 diabetes ..." | ||
| Vol 20, No 5 (2024) | Effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis of clinical trials | Abstract similar documents |
| E. M. Mezhonov, Z. M. Safiullina, Y. A. Vyalkina, S. V. Shalaev | ||
| "... " or "dabigatran" or "apixaban" or "rivaroxaban" and "vitamin K antagonist" or "warfarin" and "outcomes". ROBINS-I ..." | ||
| Vol 5, No 3 (2009) | RISK FACTORS OF THE ERECTILE DYSFUNCTION IN THE PATIENTS WITH CARDIOVASCULAR DISEASES | Abstract similar documents |
| E. V. Minakov, R. A. Khokhlov, T. N. Kuznetsova, Y. V. Popovskaya, D. V. Snustikov, E. E. Tsareva, V. I. Yarliykova, N. M. Akhmedzhanov | ||
| "... ) and/or coronary heart disease (CHD) as well as to study risk factors of erectile dysfunction. Material ..." | ||
| Vol 2, No 4 (2006) | DAILY CHANGES OF CENTRAL HEMODYNAMICS IN PATIENTS WITH CHRONIC HEART FAILURE WITH NIGHT-TIME DYSPNOEA ATTACK | Abstract similar documents |
| S. A. Dovgolis, I. G. Fomina | ||
| "... Aim. To study daily changes of central hemodynamics (CHD) in patients with chronic heart failure ..." | ||
| Vol 13, No 2 (2017) | POSSIBILITIES OF ENHANCED EXTERNAL COUNTERPULSATION USING IN CLINICAL PRACTICE | Abstract similar documents |
| Z. A. Mamieva, A. S. Lishuta, Yu. N. Belenkov, E. V. Privalova, A. O. Yusupova, S. M. Rykova | ||
| "... disease (CHD) and chronic heart failure (CHF) are considered. The mechanism of action of the EECP ..." | ||
| Vol 6, No 4 (2010) | CORRELATIONS OF LOW MOLECULAR WEIGHT PHENOTYPE OF APOPROTEIN(A) AND SERUM LEVEL OF LIPOPROTEIN(A) WITH MULTIFOCAL ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE | Abstract similar documents |
| O. I. Afanasieva, M. V. Ezhov, M. I. Afanasieva, M. S. Safarova, J. V. Berestetskaya, S. N. Pokrovsky | ||
| "... (a) [apo(a)] polymorphism with the multifocal atherosclerosis in coronary heart disease (CHD ..." | ||
| Vol 16, No 4 (2020) | Features of Structural and Functional Changes in the Heart in Elderly Patients with Coronary Heart Disease and Atrial Fibrillation | Abstract similar documents |
| L. I. Folomeeva, E. V. Filippov | ||
| "... with coronary heart disease (CHD) without heart rhythm disturbances (n=80); group 2 consisted of patients ..." | ||
| Vol 15, No 2 (2019) | Current Predictors of Atrial Fibrillation Progression | Abstract PDF (Eng) similar documents |
| V. I. Podzolkov, A. I. Tarzimanova | ||
| "... with hypertension (HT), coronary heart disease (CHD) and chronic heart failure (CHF) with recurrent AF. Material ..." | ||
| Vol 15, No 3 (2019) | Mammographic Screening as a Tool for Cardiovascular Risk Assessing. Part 2. Association of Breast Arterial Calcification and Cardiovascular Diseases | Abstract similar documents |
| E. V. Bochkareva, I. V. Kim, E. K. Butina, I. D. Stulin, S. A. Trukhanov, B. A. Rudenko, S. A. Boytsov, O. M. Drapkina | ||
| "... with a higher likelihood of myocardial infarction, death from coronary heart disease (CHD) and CVD, as well ..." | ||
| Vol 13, No 6 (2017) | FUNCTIONAL STATE OF THE MICROCIRCULATION OF THE SKIN ACCORDING TO LASER DOPPLER FLOWMETRY IN PATIENTS WITH ATRIAL FIBRILLATION WHO UNDERWENT CARDIOEMBOLIC STROKE | Abstract similar documents |
| I. A. Zolotovskaya, I. L. Davydkin, A. A. Fedorovich, O. M. Drapkina | ||
| "... analyzer for the general practitioner "LAKK-OP" in the area of the finger pad during the period, when ..." | ||
| Vol 15, No 1 (2019) | Factors Associated with Cause-Specific Death in Russia. Data from Longitudinal Prospective Study 1977-2001 | Abstract PDF (Eng) similar documents |
| S. A. Shalnova, A. V. Kapustina, A. D. Deev, Yu. A. Balanova | ||
| "... and their associations with cause-specific mortalities: coronary heart disease (CHD), stroke, cardiovascular diseases ..." | ||
| Vol 15, No 5 (2019) | Patients with History of Myocardial Infarction and Acute Cerebrovascular Accidentin Clinical Practice: Demographic, Clinical Characteristics, Drug Treatment and Outcomes (Data of Outpatient and Hospital Registry REGION) | Abstract similar documents |
| E. Yu. Okshina, M. M. Loukianov, S. Yu. Martsevich, S. S. Yakushin, N. P. Kutishenko, A. N. Vorobyev, K. G. Pereverzeva, A. V. Zagrebelnyy, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, E. V. Kudryashov, S. A. Boytsov, O. M. Drapkina | ||
| "... .2%; coronary heart disease (CHD) – 100% and 57%; chronic heart failure (CHF) – 61.5% and 41.8%; atrial ..." | ||
| Vol 18, No 4 (2022) | Respiratory Muscle Strength in Patients with Coronary Heart Disease and Different Musculoskeletal Disorders | Abstract PDF (Eng) similar documents |
| E. D. Bazdyrev, N. A. Terentyeva, N. A. Galimova, K. E. Krivoshapova, O. L. Barbarash | ||
| "... Aim. To measure respiratory muscle strength (RMS) in patients with coronary heart disease (CHD ..." | ||
| Vol 18, No 3 (2022) | Study the Association of Nucleotide Polymorphisms in Platelet Receptor and Cytochrome P450 Genes with the Development of Resistance to Antiplatelet Drugs in Patients with Coronary Artery Disease | Abstract similar documents |
| K. S. Semashchenko, T. S. Mongush, A. A. Kosinova, T. N. Subbotina, Y. I. Grinshtein | ||
| "... genes with the development of resistance to antiplatelet drugs in CHD patients. Material and Methods ..." | ||
| Vol 16, No 1 (2020) | Arrhythmias in Patients after Surgical Myocardial Revascularization | Abstract similar documents |
| N. U. Zakirov, A. G. Kevorkov, A. S. Rasulov, E. Y. Tursunov | ||
| "... changes occurring in the process of coronary heart disease (CHD) progression. The role of indicators ..." | ||
| Vol 15, No 1 (2019) | The Trends of Cardiovascular and Cancer Mortality in Russian Men and Women from 2000 to 2016 years | Abstract similar documents |
| S. A. Shalnova, O. M. Drapkina | ||
| "... coronary heart disease (CHD), cerebrovascular disease (CerVD), other CVD, and cancer, including prostate ..." | ||
| Vol 17, No 6 (2021) | Prehospital Period in Patients with COVID-19: Cardiovascular Comorbidity and Pharmacotherapy During the First Epidemic Wave (Hospital Registry Data) | Abstract similar documents |
| S. Yu. Martsevich, M. M. Lukyanov, M. M. Pulin, N. P. Kutishenko, E. Yu. Andreenko, V. P. Voronina, V. A. Dindikova, N. A. Dmitrieva, A. V. Zagrebelnyy, O. V. Lerman, A. N. Makoveeva, E. Yu. Okshina, A. A. Smirnov, E. V. Kudryashov, I. V. Budaeva, E. S. Nikoshnova, O. E. Karpov, O. M. Drapkina | ||
| "... .5%) patients with coronary heart disease (CHD), 104 (91.2%) patients with atrial fibrillation (AF ..." | ||
| Vol 19, No 1 (2023) | Incidence and Severity of Acute Myocardial Injury after Thoracic Surgery: Effects of Nicorandil | Abstract similar documents |
| K. V. Protasov, O. A. Barahtenko, E. V. Batunova, E. A. Rasputina | ||
| "... cancer patients with concomitant coronary heart disease (CHD) undergoing surgical lung resection ..." | ||
| Vol 16, No 1 (2020) | An Attempt to Accord the Quality of Therapy of Stable Coronary Heart Disease Patients with Current Clinical Guidelines (ALIGN study): Design and the First Results | Abstract similar documents |
| S. Yu. Martsevich, E. D. Zharkova, N. P. Kutishenko, Yu. V. Lukina, S. N. Tolpygina, V. P. Voronina, A. V. Zagrebelnyy | ||
| "... Aim. To assess the quality of therapy in stable coronary heart disease (CHD) patients, who first ..." | ||
| Vol 19, No 1 (2023) | Acute Coronary Syndrome during the Pandemic New Coronavirus Infection | Abstract similar documents |
| O. M. Drapkina, A. Ya. Kravchenko, A. V. Budnevskiy, A. V. Kontsevaya, E. S. Ovsyannikov, E. S. Drobysheva | ||
| "... serious damage to the cardiovascular system. However, coronary artery disease (CHD) remains the leading ..." | ||
| Vol 19, No 2 (2023) | Secondary Prevention and Quality of Life of Patients with Stable Coronary Heart Disease | Abstract similar documents |
| E. D. Zharkova, Yu. V. Lukina, N. P. Kutishenko, E. T. Huseynova, N. P. Zolotareva, S. Yu. Martsevich, O. M. Drapkina | ||
| "... Aim. To assess the quality of life of patients with stable coronary heart disease (CHD) initially ..." | ||
| Vol 18, No 5 (2022) | Clinical and Anamnestic Characteristics, Cardiovascular Pharmacotherapy and Long-term Outcomes in Multimorbid Patients after COVID-19 | Abstract similar documents |
| A. A. Smirnov, M. M. Loukianov, S. Yu. Martsevich, A. A. Pulin, N. P. Kutishenko, E. Yu. Andreenko, V. P. Voronina, V. A. Dindikova, N. A. Dmitrieva, M. M. Kudryavtseva, O. V. Lerman, A. N. Makoveeva, E. Yu. Okshina, A. A. Maltseva, E. N. Belova, V. G. Klyashtorniy, E. V. Kudryashov, O. E. Karpov, O. M. Drapkina | ||
| "... hypertension (AH), coronary heart disease (CHD), chronic heart failure (CHF), atrial fibrillation (AF ..." | ||
| Vol 14, No 6 (2018) | Cardiovascular Diseases and Drug Treatment in Patients with the History of Cerebral Stroke: Data of the Outpatient Registry REGION | Abstract PDF (Eng) similar documents |
| M. M. Loukianov, S. S. Yakushin, S. Yu. Martsevich, O. M. Drapkina, A. N. Vorobyev, A. V. Zagrebelnyy, A. N. Kozminsky, K. A. Moseichuk, K. G. Pereverzeva, E. A. Pravkina, E. Yu. Okshina, E. V. Kudryashov, E. N. Belova, V. G. Klyashtorny, S. A. Boytsov | ||
| "... for coronary heart disease (CHD) – 47.2% vs 27.9%; antiplatelet agents for CHD without atrial fibrillation – 65 ..." | ||
| Vol 16, No 5 (2020) | Comparative Characteristics of Patients with Cerebral Stroke and Myocardial Infarction in Outpatient Practice: Structure of Comorbidity, Risk Factors, Drug Treatment and Outcomes | Abstract similar documents |
| A. N. Vorobyev, K. G. Pereverzeva, M. M. Loukianov, S. S. Yakushin, S. Yu. Martsevich, E. Yu. Okshina, O. M. Drapkina | ||
| "... receptor blockers (ARBs) in CHF, beta-blockers in CHF and MI history, statins in CHD, antiplatelet agents ..." | ||
| Vol 20, No 2 (2024) | The phenomenon of complete treatment refusal in patients with acute cerebrovascular accident (according to the LIS-2 registry) | Abstract similar documents |
| Yu. V. Lukina, N. P. Kutishenko, A. V. Zagrebelny, M. L. Ginzburg, S. Yu. Martsevich, O. M. Drapkina | ||
| "... statistically significant difference in hypertension and coronary heart disease (CHD) (p<0.001 and p=0 ..." | ||
| Vol 18, No 3 (2022) | Assessment of the Quality of Drug Therapy in Patients with Stable Coronary Artery Disease in the Second Stage of the ALIGN Study | Abstract similar documents |
| E. D. Zharkova, S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, O. M. Drapkina | ||
| "... with stable coronary heart disease (CHD). Material and methods. Of the 73 patients included in the ALIGN ..." | ||
| Vol 18, No 4 (2022) | Non-High Density Lipoprotein Cholesterol: A Modern Benchmark for Assessing Lipid Metabolism Disorders | Abstract PDF (Eng) similar documents |
| S. A. Shalnova, V. A. Metelskaya, V. A. Kutsenko, E. B. Yarovaya, A. V. Kapustina, G. A. Muromtseva, G. E. Svinin, Yu. A. Balanova, A. E. Imaeva, S. E. Evstifeeva, V. G. Vilkov, O. L. Barbarash, O. A. Belova, Yu. I. Grinshtein, A. Yu. Efanov, O. N. Kalachikova, N. V. Kulakova, O. P. Rotar, I. A. Trubacheva, D. V. Duplyakov, R. A. Libis, I. A. Viktorova, A. N. Redko, S. S. Yakushin, S. A. Boytsov, E. V. Shlyakhto, O. M. Drapkina | ||
| "... population sample and the same sample without individuals with coronary heart disease (CHD), myocardial ..." | ||
| Vol 17, No 1 (2021) | Aspirin Resistance as a Result of Impaired Interaction of Platelets and Neutrophils in Patients with Coronary Heart Disease | Abstract similar documents |
| M. D. Goncharov, A. A. Savchenko, Yu. I. Grinshtein, I. I. Gvozdev, A. A. Kosinova, T. S. Mongush | ||
| "... ) by platelets and neutrophils in patients with coronary heart disease (CHD) before and after coronary artery ..." | ||
| 1 - 96 of 96 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
